Key result
Upregulated IL6 and IL10 with downregulated TLR4 emerge as central regulators of aortic dissection cell death.
Why the study?
Programmed cell death is implicated as a critical driver of aortic dissection pathogenesis, but the underlying molecular mechanisms remain poorly defined.
Multiomics analysis identifies IL6, IL10, and TLR4 as central regulators of programmed cell death in aortic dissection, highlighting them as potential therapeutic targets.
IL6/IL10/TLR4 modulation may warrant study in aortic dissection; extends animal PCD insights but should not yet change practice.
Background Aortic dissection (AD), a life‐threatening cardiovascular emergency, poses a significant threat to global cardiovascular health. Emerging evidence implicates programmed cell death (PCD) as a critical driver of AD pathogenesis, yet the molecular mechanisms remain poorly defined. This study systematically investigates PCD‐related biomarkers in AD to identify novel therapeutic targets. Methods Multiomics analysis integrated transcriptome sequencing data from eight AD and five control aortic tissues. Differentially expressed genes (DEmRNAs, n = 3094) were intersected with 1574 programmed cell death–related genes (PCD‐RGs) to identify candidate biomarkers. Protein–protein interaction (PPI) networks, functional enrichment, immune infiltration profiling, and drug‐target prediction were employed to characterize key molecular drivers. Results Three PCD‐associated biomarkers were identified: IL6 (11.8‐fold upregulated), IL10 (26.1‐fold upregulated), and TLR4 (0.38‐fold downregulated). These biomarkers exhibited significant enrichment in immunoregulatory pathways including “MYC Targets V1” (FDR < 0.05), with IL10 showing strong immune microenvironment correlations (memory B cells: r = 0.62; endothelial cells: r = −0.58). Regulatory network analysis revealed 58 transcription factors (STAT1/SP1/IRF8) and six key miRNAs (e.g., miR‐204‐5p) orchestrating biomarker expression. Drug‐target mapping identified 91 repurposable agents, including etanercept‐szzs (dual IL6/IL10 inhibitor) and TLR4‐modulating compounds. Conclusion This study establishes IL6, IL10, and TLR4 as central regulators of PCD‐mediated AD pathogenesis, implicating immune–vascular crosstalk and immunogenic cell death as therapeutic entry points. The identified biomarker network and drug candidates provide a translational framework for developing precision therapies against AD.
No takes yet. Share an insight, caveat, or question.
Du et al. (2026) studied this question. IL6 (11.8-fold upregulated), IL10 (26.1-fold upregulated), and TLR4 (0.38-fold downregulated) emerged as central regulators of programmed cell death in aortic dissection pathogenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: